Here is a brief preview of this blast: On Friday, February 17, Gilead / Kite announced (press release) that Christi Shaw (Kite’s CEO) decided to depart by the end of Q1 2023. Below, Celltelligence provides insights on Shaw’s tenure in Kite, while discussing the profile of her potential replacement.
About The Author
The Celltelligence Team
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.